Clinical
Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results
Kymera Therapeutics; KT-621; Dupixent-in-a-pill; oral STAT6 degrader; atopic dermatitis; eczema; BroADen Phase 1b trial; Dupixent rival; Type 2 inflammation; early clinical data
Imfinzi Gains FDA Approval for Early Gastric and GEJ Cancers; BiomX Nebulizer Faces FDA Scrutiny
Imfinzi; FDA approval; gastric cancer; gastroesophageal cancer; perioperative; BiomX; nebulizer; clinical hold
ViTAA Medical Secures FDA 510(k) Clearance for AiORTA Plan, Launching Its Hyper-Precise Aortic Care Platform
ViTAA Medical; FDA 510(k) clearance; AiORTA Plan; hyper-precise aortic care; automated aortic surgery planning; vascular AI; preoperative measurement automation; cloud-based healthcare; aortic aneurysm segmentation; clinical workflow improvement
WuXi AppTec Sells China-Based Clinical Research Units to Hillhouse Investment Management
WuXi AppTec; clinical services; China-based; sale; Hillhouse Investment Management; WuXi Clinical; WuXi MedKey; CRDMO strategy
WuXi AppTec Divests China Clinical Services to Hillhouse Capital, Refocuses on Manufacturing Business
WuXi AppTec; Hillhouse Capital; divestment; clinical research services; CRDMO; manufacturing; China; WuXi Clinical; MedKey
METiS BioTech Announces China’s First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
METiS BioTech; AI; drug formulation; Phase III; pseudobulbar affect (PBA); China; nanodelivery; AiTEM; clinical milestone
Addex Therapeutics’ Phase II Epilepsy Drug in Partnership with J&J Fails to Meet Endpoints
Addex Therapeutics, J&J, Phase II trial, epilepsy, drug candidate, clinical endpoints, future development.
Roche’s Ocrevus Demonstrates Near-Complete Reduction of Relapse and Lesions in Multiple Sclerosis
Ocrevus, Roche, Multiple Sclerosis (MS), Relapse reduction, Lesion reduction, Clinical and MRI measures